Approval · Notice of Compliance 7613 · 2005
RELAFEN: Notice of Compliance 7613
Issued November 15, 2005
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 7613
- Date
- November 15, 2005
- Company
- Glaxosmithkline IncMississauga, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Product monograph: safety update
- Therapeutic class
- Non-steroidal anti-inflammatory agent
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| RELAFEN | Not yet assigned | — |
Medicinal ingredients
- NABUMETONE 500 MG per TAB
- NABUMETONE 750 MG per TAB